PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
PolyPid (PYPD) Q1 2026 Earnings Transcript
PolyPid Q1 Earnings Call Highlights
PolyPid Q1 2026 Earnings Call: Complete Transcript
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
PolyPid To Present ASEPSIS Analysis Data From Its Phase 3 SHIELD II Study Of D-PLEX At 5th Annual Meeting Of The Surgical Infection Society
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Initiates New Drug Application With FDA For D-PLEX₁₀₀ For Prevention Of Colorectal Surgical Site Infections
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.